Blood test as a possible replacement for bone marrow biopsy in MPN patients
Part of Blood & lymphatic clinical trials.
This study looks at whether a simple blood test can give the same information as a bone marrow biopsy for people with myeloproliferative neoplasms (MPNs), which are blood cancers that cause the bone marrow to make too many cells. If successful, it could mean less invasive testing for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a myeloproliferative neoplasm (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF), based on standard criteria.
- You must be scheduled for a bone marrow biopsy because of a suspected MPN diagnosis.
- You cannot currently be receiving treatment for your MPN.
- You must not have had a bone marrow transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study looks at how 'epigenetic age' (a measure of certain changes in your DNA) relates to the way blood cancers called myeloproliferative neoplasms (MPNs) develop and progress. It may help doctors better understand and predict the course of these diseases.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
This study tries to see if blood tests can replace a bone marrow biopsy for people with low blood counts (cytopenia) and suspected MDS (myelodysplastic syndrome). It aims to make diagnosis less invasive by using a simple blood draw instead of a bone marrow sample.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.